"Nelfinavir" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A potent HIV protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children.
| Descriptor ID |
D019888
|
| MeSH Number(s) |
D03.633.100.531.520
|
| Concept/Terms |
Nelfinavir Mesylate- Nelfinavir Mesylate
- Mesylate, Nelfinavir
- Nelfinavir Monomethane Sulfonate
- Monomethane Sulfonate, Nelfinavir
- Sulfonate, Nelfinavir Monomethane
|
Below are MeSH descriptors whose meaning is more general than "Nelfinavir".
Below are MeSH descriptors whose meaning is more specific than "Nelfinavir".
This graph shows the total number of publications written about "Nelfinavir" by people in this website by year, and whether "Nelfinavir" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 1 | 0 | 1 |
| 2004 | 1 | 0 | 1 |
| 2016 | 2 | 0 | 2 |
| 2019 | 0 | 1 | 1 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Nelfinavir" by people in Profiles.
-
Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally advanced pancreatic cancer: The phase 1/randomised phase 2 SCALOP-2 trial. Eur J Cancer. 2024 Sep; 209:114236.
-
Study protocol: a multi-centre randomised study of induction chemotherapy followed by capecitabine ± nelfinavir with high- or standard-dose radiotherapy for locally advanced pancreatic cancer (SCALOP-2). BMC Cancer. 2019 Feb 04; 19(1):121.
-
ARCII: A phase II trial of the HIV protease inhibitor Nelfinavir in combination with chemoradiation for locally advanced inoperable pancreatic cancer. Radiother Oncol. 2016 05; 119(2):306-11.
-
Clinical Trial of Oral Nelfinavir before and during Radiation Therapy for Advanced Rectal Cancer. Clin Cancer Res. 2016 Apr 15; 22(8):1922-31.
-
Baseline HIV-1 RNA level and CD4 cell count predict time to loss of virologic response to nelfinavir, but not lopinavir/ritonavir, in antiretroviral therapy-naive patients. J Infect Dis. 2004 Jul 15; 190(2):280-4.
-
Nelfinavir, a protease inhibitor, increases sirolimus levels in a liver transplantation patient: a case report. Liver Transpl. 2002 Sep; 8(9):838-40.